H.R. 1051: To amend the Federal Food, Drug, and Cosmetic Act to allow for the approval of an abbreviated new drug application submitted by a subsequent applicant in the case of a failure by a first applicant to commence commercial marketing within a certain period, and for other purposes.
A House bill (H.R.) in the 119th U.S. Congress.
Overview
| Congress | 119th U.S. Congress (2025–2026) |
|---|---|
| Type | House bill (H.R.) |
| Originating chamber | House |
| Cosponsors | 0 |
| Latest action | 2025-02-06 — Referred to the House Committee on Energy and Commerce. |
| Last updated | 2025-06-09 |
Summary
An official summary for this measure has not been published by Congress. The full text is available on congress.gov.
Full text & official record
The official bill text, section-by-section summary, amendments, committee reports, and the complete legislative timeline for H.R. 1051 are published by Congress on congress.gov.
View H.R. 1051 on congress.gov →
Frequently asked questions
What is H.R. 1051?
H.R. 1051 is a House bill (H.R.) introduced in the 119th U.S. Congress, originating in the House. Official title: To amend the Federal Food, Drug, and Cosmetic Act to allow for the approval of an abbreviated new drug application submitted by a subsequent applicant in the case of a failure by a first applicant to commence commercial marketing within a certain period, and for other purposes..
Where can I read the full bill text?
The full text, cosponsors, amendments, and legislative status for H.R. 1051 are available on congress.gov.
Bill data: congress.gov API (official congressional records).